Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM H JOHNSTON JR.

Allopathic & Osteopathic Physicians Pediatrics

NPI
1740385764
CMS profile
33341
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$114.86

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $114.86 8

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM H JOHNSTON JR.

NPI 1740385764 · CMS profile ID 33341

Allopathic & Osteopathic Physicians / Pediatrics

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740385764?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM H JOHNSTON JR., NPI 1740385764, CMS profile ID 33341. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740385764?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). WILLIAM H JOHNSTON JR., NPI 1740385764, CMS profile ID 33341. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740385764?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
WILLIAM H JOHNSTON JR., NPI 1740385764, CMS profile ID 33341, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1740385764?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $114.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $13.0307/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695634247 CMS
Sobi, Inc $23.8103/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698088291 CMS
Teva Pharmaceuticals USA, Inc. $10.9003/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697781447 CMS
Shire North American Group Inc $13.1202/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637848989 CMS
Shire North American Group Inc $12.3702/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637848991 CMS
Hologic, LLC $12.6102/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 649997201 CMS
Shire North American Group Inc $12.8401/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637848987 CMS
ARBOR PHARMACEUTICALS, INC. $16.1801/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697405236 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $114.86 8
PY2023 $1,472.90 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $209,872.28 58
PY2024 Recipient $5,150.00 1
PY2024 Principal investigator $338,079.53 66
PY2023 Principal investigator $405,526.56 39
PY2022 Recipient $935.00 2
PY2022 Principal investigator $477,955.66 57
PY2021 Recipient $1,025.77 2
PY2021 Principal investigator $105,200.85 39
PY2020 Recipient $446.71 1
PY2020 Principal investigator $92,105.43 57
PY2019 Principal investigator $346,813.45 159

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,080.00 12/31/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 889828991
Principal investigator 1 AstraZeneca UK Limited $79.53 12/31/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES, INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 914590897
Principal investigator 1 AstraZeneca UK Limited $153.02 12/31/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 914603289
Principal investigator 1 Merck Sharp & Dohme LLC $133.51 12/31/2022 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 940395029
Principal investigator 1 Merck Sharp & Dohme LLC $66,075.82 12/31/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older No dispute reported 06/30/2026 940396405
Principal investigator 1 Merck Sharp & Dohme LLC $103.10 12/31/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older No dispute reported 06/30/2026 940396509
Principal investigator 1 Merck Sharp & Dohme LLC $101,227.31 12/31/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 940397683
Principal investigator 1 Merck Sharp & Dohme LLC $4,997.74 12/31/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 940397685
Principal investigator 1 Merck Sharp & Dohme LLC $310.34 12/31/2022 Non-covered Recipient Entity
Central Research Associates
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 964705893
Principal investigator 1 Merck Sharp & Dohme LLC $751.56 12/31/2022 Non-covered Recipient Entity
Central Research Associates
A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older No dispute reported 06/30/2026 964707263
Principal investigator 1 GlaxoSmithKline, LLC. $794.32 12/21/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 943974405
Principal investigator 1 GlaxoSmithKline, LLC. $397.16 12/21/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 943974429
Principal investigator 1 Merck Sharp & Dohme LLC $153,733.00 12/05/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 940397643
Principal investigator 1 ABBVIE INC. $130.00 12/01/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 889822363
Principal investigator 1 PFIZER INC. $150.00 11/23/2022 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949780291
Principal investigator 1 GlaxoSmithKline, LLC. $843.82 11/04/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 943974421
Principal investigator 1 GlaxoSmithKline, LLC. $2,214.94 10/26/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 943974417
Principal investigator 1 GlaxoSmithKline, LLC. $8,857.18 10/21/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 943974407
Principal investigator 1 GlaxoSmithKline, LLC. $3,280.44 10/21/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 943974411
Principal investigator 1 GlaxoSmithKline, LLC. $2,099.47 10/21/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 943974419
Principal investigator 1 PFIZER INC. $10,194.00 10/08/2022 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949791493
Principal investigator 1 PFIZER INC. $362.20 10/07/2022 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949780069
Principal investigator 1 PFIZER INC. $3,187.75 09/29/2022 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949791169
Principal investigator 1 GlaxoSmithKline, LLC. $1,832.74 09/21/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 943974413
Principal investigator 1 ModernaTX, Inc. $1,250.00 09/16/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963486567
Principal investigator 1 ModernaTX, Inc. $1,442.00 09/16/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963486573
Principal investigator 1 PFIZER INC. $526.50 08/24/2022 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949804377
Principal investigator 1 GlaxoSmithKline, LLC. $4,157.15 08/19/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943974409
Principal investigator 1 GlaxoSmithKline, LLC. $1,785.35 08/19/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943974415
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/19/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963486577
Principal investigator 1 ModernaTX, Inc. $3,000.00 08/19/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, No dispute reported 06/30/2026 963486583
Principal investigator 1 Eli Lilly and Company $19.00 07/11/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES, INC
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 917823321
Principal investigator 1 Eli Lilly and Company $82.00 07/11/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES, INC
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 917824417
Principal investigator 1 GlaxoSmithKline, LLC. $3,628.63 06/24/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943974425
Principal investigator 1 GlaxoSmithKline, LLC. $5,981.96 06/24/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 943974427
Principal investigator 1 AstraZeneca UK Limited $3,167.10 06/23/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 914599429
Principal investigator 1 PFIZER INC. $263.25 06/15/2022 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949813151
Principal investigator 1 PFIZER INC. $181.10 06/09/2022 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949791495
Principal investigator 1 PFIZER INC. $263.25 06/03/2022 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949813153
Principal investigator 1 GlaxoSmithKline, LLC. $2,318.73 05/20/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 943974423
Principal investigator 1 PFIZER INC. $633.54 05/05/2022 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949821515
Principal investigator 1 Eli Lilly and Company $29,951.00 05/03/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES, INC
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 917824415
Principal investigator 1 PFIZER INC. $452.44 04/27/2022 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949820453
Principal investigator 1 Eli Lilly and Company $337.00 04/26/2022 Non-covered Recipient Entity
SOUTHERN CALIFORNIA DERMATOLOGY INC
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 917841291
Principal investigator 1 PFIZER INC. $789.75 04/21/2022 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949820177
Principal investigator 1 PFIZER INC. $1,791.94 03/31/2022 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949820625
Recipient Eli Lilly and Company $891.00 03/28/2022 Covered Recipient Physician PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 917818781
Principal investigator 1 PFIZER INC. $1,842.75 03/23/2022 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949826175
Principal investigator 1 Allergan, Inc. $270.00 03/08/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864373461
Principal investigator 1 PFIZER INC. $1,849.25 03/03/2022 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949826207
Recipient Eli Lilly and Company $44.00 02/23/2022 Covered Recipient Physician A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 917818785
Principal investigator 1 UPSHER-SMITH LABORATORIES LLC $1,500.00 02/16/2022 Non-covered Recipient Entity
MRA CLINICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE No dispute reported 06/30/2026 907466913
Principal investigator 1 PFIZER INC. $2,761.85 02/05/2022 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949829897
Principal investigator 1 Eli Lilly and Company $316.00 01/31/2022 Non-covered Recipient Entity
SOUTHERN CALIFORNIA DERMATOLOGY INC
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 917844861
Principal investigator 1 Eli Lilly and Company $38,299.00 01/25/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES, INC
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 917824413
Principal investigator 1 PFIZER INC. $452.44 01/12/2022 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949820627
Principal investigator 1 PFIZER INC. $2,244.38 01/07/2022 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949821513
Principal investigator 1 PFIZER INC. $263.25 01/07/2022 Non-covered Recipient Entity
Central Research Associates Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949831217
Principal investigator 1 AstraZeneca UK Limited $1,646.10 01/04/2022 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES, INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 914593227